The Filing Desk

C4 Therapeutics vs Precision Biosciences

C4 Therapeutics CCCC · Precision Biosciences DTIL · Biotechnology

C4 Therapeutics reported revenue of $36 million in fiscal 2025, about the same as Precision Biosciences' $34 million in fiscal 2025. C4 Therapeutics' revenue grew 1.0% in its latest year, and Precision Biosciences' fell 50.1%. C4 Therapeutics had an operating margin of -320.5%, against -152.2% at Precision Biosciences. Free cash flow was −$99 million at C4 Therapeutics and −$66 million at Precision Biosciences.

Side by side

C4 TherapeuticsPrecision Biosciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$36M$34M
Revenue growth1.0%−50.1%
Revenue growth a year, last 5 years—7.1%
Gross margin——
Operating margin−320.5%−152.2%
Net margin−292.1%−133.4%
Free cash flow−$99M−$66M
Free cash flow margin−276.2%−192.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count19.5%86.3%
Last close$2.44$6.91
P/E at the last close——
Insider trades, last 12 monthssold $22,200bought $63,215, sold $412,359
Piotroski F-score3 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
C4 TherapeuticsPrecision Biosciences
Operating margin
Percent of revenue
C4 TherapeuticsPrecision Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
C4 TherapeuticsPrecision Biosciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the C4 Therapeutics and Precision Biosciences pages.